Phase II neoadjuvant vemurafenib trial in melanoma patients with untreated brain metastases with B-raf mutations
What is the purpose of this trial?
- To determine the brain metastasis response rate in patients treated with vemurafenib prior to local therapy (LITT, SRS or resection).
- To evaluate tumor BBB passage of vemurafenib in a subset of patients, as determined by levels of drug in brain metastases and levels of pERK in tumor.
- 18 Years and older
- Genentech, Inc.
- Last Updated:
- Study HIC#: